Sapient

As investment in and approvals for GLP-1 therapies continue to accelerate, sponsors must ensure their development efforts can keep pace. Discovery #metabolomics can provide an unprecedented view into metabolic changes induced by GLP-1 agonists, revealing #biomarkers can be applied for: ?? Deepening #GLP1 mechanistic insights? ?? Patient stratification in GLP-1 agonist #clinicaltrials ?? Safety profiling of GLP-1 therapy ?? Expansion of GLP-1 agonist indications Learn more about how nontargeted profiling of dynamic biomarkers can uncover novel biological insights that drive greater competitive advantages. https://lnkd.in/gRqn_DGD

#Multiomics innovation was on display last week at Oxford Global's Multi-Omics in Biomarker Discovery & Precision Medicine Online Symposium! We thank all the speakers and delegates that joined us to share how they are integrating multi-omics technologies and techniques into therapeutic R&D. If you weren't able to make the live symposium, you can still watch Sapient's feature session, presented by Dr. Jonathan Usuka, here: https://lnkd.in/gHFYrBwZ

We're #hiring a new Business Development/Sr Business Development Director in San Diego Metropolitan Area. Apply today or share this post with your network.

#Hiring: We are seeking a highly motivated, detail-oriented ???????????????? ?????????????????????? ???????????????? to join our growing commercial team. If you're interested in building?long-lasting client relationships by empowering pharma and biotech sponsors with actionable insight to advance their drug programs successfully, #apply today: https://lnkd.in/gejM6iD9 #careers #businessdevelopment #BD #SapientTeam

"There are diseases in which the #genome does change—cancer being the prime example, as there are mutations that occur. But what about other diseases for which the genome is not changing? Heart disease, GI illness, liver disease, immunology and inflammatory diseases, fibrotic diseases, neurodegenerative diseases and renal disease are all examples with limited genetic influence. How do we begin to interrogate that? That is the basis of Sapient going #beyondthegenome, being able to understand the dynamic #biomarkers that can read out a person’s health, future disease risk, what drugs they’re going to respond to. This is information we're trying to capture to complement their underlying genomic risk score." Read more from Mo Jain, MD PhD's recent interview with Biocom California discussing the exciting strides being made in #multiomics technology to allow for large-scale discovery of dynamic #biomarkers. See how these protein, metabolite, and lipid markers are being applied in precision medicine programs today: https://lnkd.in/gc-YvD-m

We're #hiring a new Head of Proteomics in San Diego Metropolitan Area. Apply today or share this post with your network.

?????????????? Shaun Chen ???? ?????????????? ???? ???????? ?????????????????? ????! We are excited to share that Shaun has joined our data science team, bringing expertise in complex bioinformatics and machine learning/deep learning models to advance disease prevention and treatment. Shaun completed his PhD at The Scripps Research Institute, where he focused on developing ML frameworks for risk prediction and targeted interventions using biobank data integrated with multi-modal datasets and longitudinal electronic health records. He also earned his Master’s degree in Molecular and Cellular Biology from National Taiwan University. ?? ???????????? ???? ???????????? On what drives him in his work, Shaun says it is the opportunity to contribute to research that improves health outcomes for individuals. “I've always been intrigued by the patterns in nature and biology—and the more I learned about the complexities of human health, the more passionate I became about using these insights to help prevent diseases through personalized medicine. I’m excited to collaborate with Sapient’s interdisciplinary team to apply cutting-edge models that transform multi-omics data into actionable healthcare solutions.” Please join us in welcoming Shaun to the #SapientTeam!

???????????????? ???????????????????????????? & ???????????????????????? - ???????? ???? MyOme & Broad Clinical Labs partner with Southern Research on ???????????????? program PacBio's short read sequencing instrument?Onso? instrument joins 10x Genomics compatible partner program PacBio & National Cancer Centre Singapore to study the genomics of prevalent cancers in Asia. Delve Bio & Broad Clinical Labs partner to improve access to metagenomic sequencing for neurological infections patients Myriad Genetics announced 5 research collaborations to study the use of the company's Precise MRD assay in breast cancer minimal residual disease monitoring. LGC Clinical Diagnostics & AccuGenomics partner to develop QC materials for NGS tests. Velsera & Diagnostica Longwood to accelerate the adoption of sequencing-based precision medicine in Spain & Portugal nextgen-dx.com & Shionogi & Co., Ltd?to develop models for predicting microbial susceptibility to cefiderocol Codexis, Inc. inked a nonexclusive commercial and manufacturing license agreement for enzymes in its life science portfolio with?Alphazyme LLC Owkin & AstraZeneca to develop an AI-based prescreening tool for gBRCA mutations in breast cancer. Seegene Inc. &Werfen to bring syndromic rtPCR testing to Spain Zymo Research Corp & BluMaiden Biosciences to provide clinical trial analytics & reporting services based on the human microbiome to pharmaceutical companies. Tempus AI strikes cancer drug research deal with JW Pharmaceutical Corporation Sapient partners with Rancho BioSciences to expand and refine its multiomics database. Caris Life Sciences & ECOG-ACRIN Cancer Research Group partner to analyze breast tumour samples from landmark TAILORx study. #collaboration #lifescience #biotech #genomics #proteomics #diagnostics #genetic #spatialomics

Today is #WorldDiabetesDay: a great opportunity to raise awareness to improve prevention, diagnosis, and management of diabetes mellitus, and to highlight the exciting science that is helping to drive these initiatives forward for public health. Multifactorial conditions such as diabetes require comprehensive characterization for proper diagnosis and treatment. This recent review shows the power of #multiomics to identify novel diabetes mellitus #biomarkers, compiling results from numerous papers that have applied omics to elucidate early biomarkers and new diagnostic techniques for type 1 diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes mellitus (GDM). https://lnkd.in/gPsZHMBh At Sapient, we're proud to contribute to #diabetes research & drug development through the discovery of dynamic metabolite, lipid, and protein biomarkers that improve early disease prediction, diagnosis, patient stratification, and drug response monitoring. We'll continue to work to accelerate these discoveries that can reduce risk of diabetes and improve quality of life for those with the disease.

Thank you to Bruker for inviting us to speak at the Life Science Mass Spec Users Meeting on using #multiomics data to accelerate drug discovery. Many great questions were asked by the audience and there is clear interest and opportunity in leveraging #massspectrometry methods to enable both broad-scale and targeted #proteomics, #metabolomics, and #lipidomics for drug development. If you have questions on how these approaches can be applied in your studies, reach out to set a time to talk!: https://lnkd.in/grcp4BZg